IPCI is a boring, generic drug company, it does not worth much at all
The FOOL article did not mention that why all the FOOL's articles on AVXL have been soft bashing articles without any rock-solid scientific backup.
The FOOL's article did not explain why AXON has a failed anti-Alzheimer's drug (in clinical trial) and has a market cap about 1.5 billion.
The FOOL's article did not mention that which company has the most promising anti-Alzheimer's drug in the clinical trials
The FOOL's article did not mention the fundamental sciences and what achievements AVXL has made so far.
The FOOL article did not mention that the analyst-claimed, Biogen's 20 billion dollar anti-Alzheimer's disease drug has failed miserably in its clinical trial.